Effect of Barberry on Non Alcoholic

The Effect of Berberis Vulgaris Fruits Extract on Alanine Aminotransfrase ,Aspartate Aminotransfrase,Serum Lipid and Fasting Blood Glucose of Non-Alcoholic Steatohepatitis in Patients Referred to Clinic Martyr Motahhari Shiraz in 1390

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202068505N2

Enrollment

Registered

2012-09-20

Start date

2011-07-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic Steatohepatitis. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group : 750 mg of Berberis Vulgaris Fruits Extract, BID during 3 months. Intervention 2: Control group : placebo, with same shape, color and packaging without active drug.

Treatment - Drugs

Placebo

Intervention group : 750 mg of Berberis Vulgaris Fruits Extract, BID during 3 months

Control group : placebo, with same shape, color and packaging without active drug.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Including criteria : older than 20 years with nonalcoholic- fatty liver disease; liver enzymes>42 and proportion of ALT/ AST>1. Excluding criteria : using drugs that affect liver tests during the last 2 months; viral hepatitis; hemochromatosis; autoimmune hepatitis; cirrhosis;type 1 diabetes; alcohol dependency; pregnancy; breast feeding and infectious diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ALT. Timepoint: Before, 45 days and 3 month after the therapy. Method of measurement: Laboratory.;AST. Timepoint: Before, 45 days and 3 month after the therapy. Method of measurement: Laboratory.;FBS. Timepoint: Before, 45 days and 3 month after the therapy. Method of measurement: Laboratory.	—

Secondary

Measure	Time frame
Chol-T. Timepoint: Before and 3 months after the therapy. Method of measurement: laboratory.;Triglycirid. Timepoint: Before and 3 months after the therapy. Method of measurement: laboratory.;LDL. Timepoint: Before and 3 months after the therapy. Method of measurement: laboratory.;HDL. Timepoint: Before and 3 months after the therapy. Method of measurement: laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRaziye Iloun Kashkooli

Shiraz University of Medical Sciences

raziiloon@yahoo.com+98 71 1840 3755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026